Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vicplas InternationalSGX:569 EBITDA Margin % is 3.46% as of Jan. 2026, which is 68% below its 10-year median of 10.87. The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Vicplas International ranks worse than 56.13% on this metric.
Vicplas International (SGX:569) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vicplas International EBITDA Margin % Related Terms
Vicplas International EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vicplas International's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:569 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Vicplas International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicplas International EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vicplas International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vicplas International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicplas International (SGX:569) has a EBITDA Margin % of 3.46% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vicplas International and its competitors. This is 68% below median its historical median of 10.87. Over the past decade, Vicplas International's EBITDA Margin % has ranged from 4.31 to 16.70. According to the industry distribution chart, Vicplas International ranks #458 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 56.1%.
Is Vicplas International's EBITDA Margin % too high?
Vicplas International's current EBITDA Margin % of 3.46% is 68% below median its 10-year median of 10.87. Over the past 10 years, this metric has ranged from a low of 4.31 to a high of 16.70. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Vicplas International's value of 3.46% is 54% below this industry median. Based on the distribution chart, Vicplas International ranks #458 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Vicplas International's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vicplas International ranks #458 out of 816 companies for EBITDA Margin %. This places Vicplas International in the lower half of its industry. The industry median EBITDA Margin % is 7.52. Vicplas International's value of 3.46% is 54% below this benchmark. Historically, Vicplas International's own EBITDA Margin % has ranged from 4.31 to 16.70 over the past decade. While the company's 10-year median is 10.87 vs. the industry median of 7.52, Vicplas International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vicplas International's current EBITDA Margin % of 3.46% is 54% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vicplas International and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vicplas International's current EBITDA Margin % is 3.46%, which is 68% below median its own 10-year median of 10.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicplas International stock overvalued right now?
Based on GuruFocus' analysis, Vicplas International (SGX:569) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.11, compared to a current price of S$0.08 — trading 30% below its estimated fair value. The current EBITDA Margin % is 3.46%, which is 68% below median its 10-year median of 10.87 and 54% below the Medical Devices & Instruments industry median of 7.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vicplas International (SGX:569), the current EBITDA Margin % is 3.46% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicplas International Ltd is an investment holding company. The company is organized into two main business activities: the Pipes and Pipe Fitting segment and the Medical Devices segment, which is the key revenue driver. Pipes and Pipe Fittings segment engages in the manufacturing and distribution of plastic building products, including uPVC pipes and pipe fittings and electrical conduits. The Medical device segment is involved in the research, design, development, and manufacture of medical devices. The company generates majority of its revenue from medical devices. The company does its sales through geographical segments that include Singapore, Malaysia, Mexico, China, and the United Kingdom, of which the majority of the revenue comes from Singapore.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:569 has been successfully added to your 
